Venous Thromboembolism Risk Assessment Models in Obstetrics: A Review of Current Practices and Future Directions

Abstract

Pregnancy is a major risk factor for venous thromboembolism (VTE) and its associated complications. The hypercoagulable state in both the antenatal and postnatal periods contributes to thromboembolism and continues to be a leading cause of maternal morbidity and mortality worldwide. The non-specific signs and symptoms of VTE in pregnancy and the lack of specific Risk Assessment Models (RAMs) propose a diagnostic challenge in the obstetric population. This review aims to discuss and compare existing RAMs and highlights the important challenges of using established RAMs in obstetric patients. It also emphasizes the importance of enhancing and individualizing RAMs in obstetrics to improve maternal healthcare.

Key Points

• VTE is a major complication of pregnancy, associated with increased maternal morbidity and mortality.

• VTE RAMs lack sensitivity and specificity in stratifying VTE risk in pregnancy.

• Validating VTE RAMs in the obstetric population aims to improve maternal outcomes.

Keywords

venous thromboembolism - pulmonary embolism - risk assessment model - pregnancy

Publikationsverlauf

Eingereicht: 27. April 2021

Angenommen: 18. Februar 2022

Accepted Manuscript online:
02. März 2022

Artikel online veröffentlicht:
06. Mai 2022

• References

• 1 Improving Health Care Response to Maternal Venous Thromboembolism | California Maternal Quality Care Collaborative.. Cmqcc.org. 2018 . Accessed February 2021 at: https://www.cmqcc.org/resources-toolkits/toolkits/improving-health-care-response-maternal-venous-thromboembolism
• 2 What is Venous Thromboembolism?.. Centers for Disease Control and Prevention. 2020 . Accessed February 2021 at: https://www.cdc.gov/ncbddd/dvt/facts.html
• 3 Porembskaya O, Toropova Y, Tomson V. et al. Pulmonary artery thrombosis: a diagnosis that strives for its independence. Int J Mol Sci 2020; 21 (14) 5086
• 4 Abe K, Kuklina EV, Hooper WC, Callaghan WM. Venous thromboembolism as a cause of severe maternal morbidity and mortality in the United States. Semin Perinatol 2019; 43 (04) 200-204
• 5 Devis P, Knuttinen MG. Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management. Cardiovasc Diagn Ther 2017; 7 (Suppl. 03) S309-S319
• 6 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 196: thromboembolism in pregnancy. Obstet Gynecol 2018; 132 (01) e1-e17
• 7 Croles FN, Nasserinejad K, Duvekot JJ, Kruip MJ, Meijer K, Leebeek FW. Pregnancy, thrombophilia, and the risk of a first venous thrombosis: systematic review and Bayesian meta-analysis. BMJ 2017; 359: j4452
• 8 Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011-2013. Obstet Gynecol 2017; 130 (02) 366-373
• 9 McLintock C. Thromboembolism in pregnancy: challenges and controversies in the prevention of pregnancy-associated venous thromboembolism and management of anticoagulation in women with mechanical prosthetic heart valves. Best Pract Res Clin Obstet Gynaecol 2014; 28 (04) 519-536
• 10 Bates SM, Middeldorp S, Rodger M, James AH, Greer I. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 92-128
• 11 Servante J, Swallow G, Thornton JG. et al. Haemostatic and thrombo-embolic complications in pregnant women with COVID-19: a systematic review and critical analysis. BMC Pregnancy Childbirth 2021; 21 (01) 108
• 12 Lee SY, Chien DK, Huang CH, Shih SC, Lee WC, Chang WH. Dyspnea in pregnancy. Taiwan J Obstet Gynecol 2017; 56 (04) 432-436
• 13 Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e691S-e736S
• 14 Tooher R, Gates S, Dowswell T, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2010; (05) CD001689
• 15 Ellis-Kahana J, Sparks AD, Gimovsky AC, James AH, Ahmadzia HK. Developing a model for predicting venous thromboembolism in obese pregnant women in a national study. Thromb Res 2020; 191: 42-49
• 16 Kucher N, Koo S, Quiroz R. et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352 (10) 969-977
• 17 Barbar S, Noventa F, Rossetto V. et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8 (11) 2450-2457
• 18 Obi AT, Pannucci CJ, Nackashi A. et al. Validation of the Caprini Venous Thromboembolism Risk Assessment Model in critically Ill surgical patients. JAMA Surg 2015; 150 (10) 941-948
• 19 Sultan AA, West J, Grainge MJ. et al. Development and validation of risk prediction model for venous thromboembolism in postpartum women: multinational cohort study. BMJ 2016; 355: i6253
• 20 Lamont MC, McDermott C, Thomson AJ, Greer IA. United Kingdom recommendations for obstetric venous thromboembolism prophylaxis: evidence and rationale. Semin Perinatol 2019; 43 (04) 222-228
• 21 Darzi AJ, Repp AB, Spencer FA. et al. Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. Blood Adv 2020; 4 (19) 4929-4944
• 22 Chapter 4.. Choose the Model To Assess VTE and Bleeding Risk. Agency for Healthcare Research and Quality.. 2016 . Accessed September 2021 at: https://www.ahrq.gov/patient-safety/resources/vtguide/guide4.html
• 23 Gerotziafas GT, Papageorgiou L, Salta S, Nikolopoulou K, Elalamy I. Updated clinical models for VTE prediction in hospitalized medical patients. Thromb Res 2018; 164 (Suppl. 01) S62-S69
• 24 Tran JP, Stribling SS, Ibezim UC. et al. Performance of risk assessment models for peripartum thromboprophylaxis. Reprod Sci 2019; 26 (09) 1243-1248
• 25 Sibai BM, Rouse DJ. Pharmacologic thromboprophylaxis in obstetrics: broader use demands better data. Obstet Gynecol 2016; 128 (04) 681-684
• 26 Palmerola KL, D'Alton ME, Brock CO, Friedman AM. A comparison of recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from three major guidelines. BJOG 2016; 123 (13) 2157-2162
• 27 Spyropoulos AC, Anderson Jr FA, FitzGerald G. et al; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140 (03) 706-714
• 28 Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005; 51 (2-3): 70-78
• 29 Bates SM, Rajasekhar A, Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2 (22) 3317-3359
• 30 Rodger M. Pregnancy and venous thromboembolism: ‘TIPPS’ for risk stratification. Hematology (Am Soc Hematol Educ Program) 2014; 2014 (01) 387-392
• 31 Goecke T, Voigt F, Rath W. Thromboprophylaxis following cesarean section - a nation-wide survey from Germany. J Matern Fetal Neonatal Med 2020; 33 (14) 2359-2365
• 32 Gomez D, Orfanelli T, Awomolo A, Doulaveris G, Rosen T, Duzyj C. A comparison of pregnancy-specific risk scoring systems for venous thromboembolic pharmacoprophylaxis in hospitalized maternity patients. J Matern Fetal Neonatal Med 2022; 35 (18) 3579-3586
• 33 Darzi AJ, Karam SG, Charide R. et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood 2020; 135 (20) 1788-1810
• 34 Vazquez SR, Kahn SR. Postthrombotic syndrome. Cardiology patient page. Circulation 2010; 121 (08) e217-e219